PLIANT THERAPEUTICS, INC.·4

Jun 12, 5:00 PM ET

Huh Hoyoung 4

Research Summary

AI-generated summary

Updated

Pliant Therapeutics (PLRX) Director Huh Hoyoung Receives 70,000-Share Grant

What Happened

  • Director Huh Hoyoung was granted a 70,000-share derivative award (listed as a grant, Form 4 code "A") on 2026-06-11. The filing reports an acquisition price of $0.00 and a reported total value of $0 on the Form 4. The footnote to the filing indicates these are options that vest and become exercisable on a schedule described below.

Key Details

  • Transaction date: 2026-06-11; filing date: 2026-06-12 (appears timely).
  • Instrument: derivative grant (option) for 70,000 shares; reported acquisition price $0.00.
  • Vesting schedule (per footnote): 25% vest and become exercisable on each of Oct 1, 2026; Jan 1, 2027; and Apr 1, 2027; the remaining 25% vests on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders — all subject to continued service as a director.
  • Shares owned after transaction: not disclosed in the provided filing.
  • Filing code: A = award/grant. No 10b5-1, tax-withholding, or sale noted in this filing.

Context

  • This is a compensation-related option grant to a director rather than an open-market purchase or sale. The award vests over time and does not reflect an immediate cash outflow or sale of shares. Such grants are common for board compensation; they establish future potential ownership if vesting and exercisability conditions are met.